EW-7203, EW-7195, and EW-7197, specific TGFβ/ALK5 inhibitors available as orally administered drugs [115, 116], have been shown to inhibit EMT in both TGFβ treated breast cancer cells and 4T1 orthotropic xenograft mice [117]. Here, TGFB1 is linked to breast carcinoma.